FDA Panel Split on PARP Inhibitor for Pancreatic Cancer

]]>(MedPage Today) -- SILVER SPRING, Md.--An FDA advisory panel was divided on whether olaparib (Lynparza) should be approved for maintenance treatment of metastatic pancreatic cancer patients with germline BRCA mutations.On the question of...